JOT Automation and Tensor ID Work on Syringe Inspection Platform - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

JOT Automation and Tensor ID Work on Syringe Inspection Platform


JOT Automation, a supplier of test and production solutions, and Tensor ID, specialists in machine vision solutions, will highlight the benefits of the companies' combined service and technology offering at ATX West as the companies exhibit together for the first time. The companies have started to codevelop a fully automated solution for the quality assurance of auto-injector syringes.

"Together we are pre-promoting an auto injection syringe inspection platform. The vision-based platform enables inspection of silicone coating inside glass syringes,” said Jorma Venäläinen, business line director of Life Sciences at JOT Automation, in the press release.

“The quality of silicone oil and its distribution on the inner syringe surface are two important factors that affect the injection performance of auto-injector devices. To better identify and screen out syringes with insufficient or non-uniform silicone oil distribution, our new technology visualizes, quantifies, and analyzes silicone oil distribution.”

"The market for auto-injectors is set to rise to 1.07 billion dollars by 2015," said Stacey Swall from Tensor ID in the press release. "In addition we see possibilities to exploit this technology for quality inspection of pipettes, vials and tubes.”

Source: JOT Automation

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here